Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of prostate cancer. Additionally, the ongoing clinical development of investigational therapies such as Peluntamig (PT217; Phanes Therapeutics), Tarlatamab (AMG 757; Amgen), Pembrolizumab (KEYTRUDA; Merck Sharp & Dohme), Nivolumab (OPDIVO) + Ipilimumab (YERVOY) (Bristol-Myers Squibb), and others is expected to expand the treatment landscape and address unmet medical needs.

LAS VEGAS, Oct. 15, 2026 /PRNewswire/ -- Recently published Neuroendocrine Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, neuroendocrine prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Neuroendocrine Prostate Cancer Market Summary

• The market size for neuroendocrine prostate cancer was found to be USD 5 million in the 7MM in 2025.
• The United States accounted for the largest neuroendocrine prostate cancer treatment market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total number of incident cases of NEPC in the 7MM was approximately 24,500 in 2025.
• Leading neuroendocrine prostate cancer companies, such as Phanes Therapeutics, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Daiichi Sankyo, Moonlight Bio, SystImmune, and others, are developing new neuroendocrine prostate cancer treatment drugs that can be available in the neuroendocrine prostate cancer market in the coming years. 
• The promising neuroendocrine prostate cancer therapies in clinical trials include Peluntamig (PT217), Tarlatamab (AMG 757), Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO) + Ipilimumab (YERVOY), sac-TMT, Gocatamig, ML261, [225Ac]Ac-ETN029, BL-M14D1, and others.

Discover new treatment for neuroendocrine prostate cancer @ https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market

Key Factors Driving the Growth of the Neuroendocrine Prostate Cancer Market 

• Rising Incidence of Neuroendocrine Prostate Cancer: The increasing recognition of NEPC, particularly among patients with advanced or treatment-resistant prostate cancer, is expanding the addressable patient population. Greater awareness of neuroendocrine differentiation is also supporting earlier identification of these aggressive tumors.
• Growing Investment in Targeted and Precision Therapies: Advances in molecular profiling and tumor characterization are improving understanding of the biological mechanisms underlying NEPC. These developments are encouraging pharmaceutical companies to investigate targeted therapies, biomarker-driven approaches, and combination regimens.
• Advancements in Diagnostic and Molecular Profiling Technologies: Improvements in immunohistochemistry, genomic testing, circulating tumor DNA analysis, and other molecular techniques are facilitating the identification and characterization of neuroendocrine features. Better diagnostic capabilities may improve patient stratification and increase recognition of NEPC cases.
• Expansion of Clinical Research and Drug Development: Increasing clinical-trial activity is supporting the evaluation of novel therapies for NEPC, including Peluntamig (PT217; Phanes Therapeutics), Tarlatamab (AMG 757; Amgen), Pembrolizumab (KEYTRUDA; Merck Sharp & Dohme), Nivolumab (OPDIVO) + Ipilimumab (YERVOY) (Bristol-Myers Squibb), and others. A broader development pipeline could expand future treatment options and market opportunities.

Download the report to understand the top emerging neuroendocrine prostate cancer drugs @ Neuroendocrine Prostate Cancer Clinical Trials

As per Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, following regulatory approval, tarlatamab (IMDELLTRA) is anticipated to achieve rapid market uptake in the NEPC treatment landscape, supported by the significant unmet need, limited therapeutic alternatives, and its differentiated mechanism of targeting DLL3-expressing tumors. 

DelveInsight's Neuroendocrine Prostate Cancer Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology, treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning. 

Neuroendocrine Prostate Cancer Market Analysis

• The current treatment landscape for neuroendocrine prostate cancer is primarily focused on slowing disease progression and extending survival through systemic anticancer therapies. 
• However, treatment options remain limited, and durable responses are relatively uncommon, largely owing to the aggressive nature of NEPC and its high degree of therapeutic resistance. 
• Platinum-based chemotherapy continues to form the backbone of treatment, alongside other systemic therapies, with treatment selection generally guided by disease characteristics and individual patient factors. 
• Despite the availability of these treatment approaches, clinical outcomes remain unfavorable, highlighting a significant need for more effective and targeted therapies.
• Several emerging therapies are currently being investigated to address these unmet needs in NEPC, including ifinatamab deruxtecan, being developed by Merck and Daiichi Sankyo; IMDELLTRA (tarlatamab) from Amgen; gocatamig from Merck and Daiichi Sankyo; sacituzumab tirumotecan from Merck; peluntamig (PT217) from Phanes Therapeutics; and other investigational candidates.

Neuroendocrine Prostate Cancer Competitive Landscape

Some of the neuroendocrine prostate cancer drugs under development include Peluntamig (PT217; Phanes Therapeutics), Tarlatamab (AMG 757; Amgen), Pembrolizumab (KEYTRUDA; Merck Sharp & Dohme), Nivolumab (OPDIVO) + Ipilimumab (YERVOY) (Bristol-Myers Squibb), sac-TMT (Merck), Gocatamig (Merck/Daiichi Sankyo), ML261 (Moonlight Bio), [225Ac]Ac-ETN029 (Amgen), BL-M14D1 (SystImmune), and others.

Phanes Therapeutics' Peluntamig (PT217) is a first-in-class, native IgG-like bispecific antibody that simultaneously targets DLL3 and CD47. It is designed to selectively recognize DLL3-expressing tumor cells while inhibiting the CD47 "do not eat me" signal, thereby promoting macrophage-mediated phagocytosis and enhancing anti-tumor immune activity. PT217 is under development for SCLC and neuroendocrine carcinomas (NECs), including neuroendocrine prostate cancer (NEPC), and has received Fast Track designation (FTD) for patients with metastatic de novo or treatment-emergent NEPC. Phanes Therapeutics has also established a clinical supply agreement with Roche to investigate PT217 in combination with the anti-PD-L1 antibody atezolizumab.

The ongoing Phase I/II SKYBRIDGE study is assessing the safety, tolerability, pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy of PT217 as a monotherapy and in combination therapies in patients with advanced or refractory DLL3-expressing malignancies, including SCLC and other neuroendocrine cancers.

Amgen's Tarlatamab (AMG 757) is a first-in-class DLL3-directed bispecific T-cell engager (BiTE) immunotherapy being developed for SCLC and NEPC. The therapy works by bringing CD3-positive T cells into close proximity with DLL3-expressing tumor cells, thereby stimulating targeted T-cell-mediated tumor cell killing. Tarlatamab is being evaluated across a broad clinical development program, including an ongoing Phase II study in patients with DLL3-positive metastatic prostate cancer, including NEPC. The study is evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of tarlatamab in this patient population.

Merck's Sacituzumab tirumotecan is an investigational TROP2-targeted antibody-drug conjugate (ADC) designed to selectively bind to TROP2-expressing tumor cells and deliver a potent topoisomerase I inhibitor payload. By combining targeted tumor cell recognition with intracellular delivery of a cytotoxic agent, sacituzumab tirumotecan may enhance antitumor activity in patients with advanced solid tumors, including neuroendocrine prostate cancer (NEPC). The therapy is currently being investigated in Phase II clinical development.

Merck/Daiichi Sankyo's Ifinatamab deruxtecan is an investigational B7-H3-directed antibody-drug conjugate designed to selectively bind to B7-H3-expressing tumor cells and deliver a potent cytotoxic payload. Through targeted tumor recognition and localized drug delivery, the therapy is being developed to enhance antitumor activity in patients with prostatic neoplasms. Ifinatamab deruxtecan is currently being evaluated in Phase III clinical development.

The anticipated launch of these emerging therapies are poised to transform the Neuroendocrine Prostate Cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Neuroendocrine Prostate Cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pipeline drugs could transform neuroendocrine prostate cancer treatment @ Neuroendocrine Prostate Cancer Medications

Recent Developments in the Neuroendocrine Prostate Cancer Market

• In May 2026, Amgen reported results from the Phase II TIDAL study evaluating the DLL3-directed T-cell engager tarlatamab in patients with DLL3-positive metastatic prostate cancer at the 2026 ASCO Annual Meeting.
• In March 2026, Daiichi Sankyo reported efficacy and safety data for the DLL3-targeted T-cell engager gocatamig in patients with NEPC and other neuroendocrine neoplasms, demonstrating promising clinical activity with a manageable safety profile.

Neuroendocrine Prostate Cancer Epidemiology Segmentation

The neuroendocrine prostate cancer epidemiology section provides insights into the historical and current neuroendocrine prostate cancer patient pool and forecasted trends for the leading markets. Approximately 18,600 incident cases of NEPC patients were estimated to express DLL3 in 2025 across the 7MM, highlighting a substantial biomarker-defined population eligible for emerging targeted therapies.

The neuroendocrine prostate cancer treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of NEPC
• De novo NEPC Cases 
• T-NEPC Cases 
• Stage-specific Cases of NEPC
• DLL3-expressing Cases of NEPC
• Histology subtype-specific Cases of NEPC
• Age-specific Cases of NEPC
• Total Treated Cases of NEPC

Scope of the Neuroendocrine Prostate Cancer Market Report

• Neuroendocrine Prostate Cancer Patient Population Forecast
• Neuroendocrine Prostate Cancer Therapeutics Market Size
• Neuroendocrine Prostate Cancer Pipeline Analysis
• Neuroendocrine Prostate Cancer Market Size and Trends
• Neuroendocrine Prostate Cancer Market Opportunity
• Neuroendocrine Prostate Cancer Market Unmet Needs
• KOL's Views on Neuroendocrine Prostate Cancer
• Neuroendocrine Prostate Cancer Market Access and Reimbursement

Table of Contents

Related Reports

Neuroendocrine Tumors Market

Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies, including ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixi, BMS, RayzeBio, Radiomedix, OranoMed, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, Elicera Therapeutics, and others.

Prostate Cancer Market

Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.

Radioligand Therapies Market

Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others.

PSMA-targeted Therapy Market

PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

www.delveinsight.com   

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroendocrine-prostate-cancer-market-to-witness-growth-at-a-25-cagr-by-2036-due-to-the-emergence-of-emerging-agents-including-dll3-targeted-therapies-adcs-bsabs-car-ts-aurora-kinase-inhibitors-and-ezh2-inhibitors--delvein-302908174.html

SOURCE DelveInsight Business Research, LLP